Spot Urine Albumin-to-Creatinine Ratio
The most appropriate screening test for this patient is the spot urine albumin-to-creatinine ratio (UACR). This is the gold standard screening test recommended by current guidelines for detecting early diabetic nephropathy in patients with type 2 diabetes 1, 2.
Why UACR is the Correct Answer
The 2025 ADA Standards of Care explicitly state that "screening for albuminuria can be most easily performed by urine albumin-to-creatinine ratio (UACR) in a random spot urine collection" 1. The ADA/KDIGO consensus further reinforces that annual screening should include spot urine ACR (albumin-to-creatinine ratio) starting at diagnosis for type 2 diabetes 2.
Key Advantages of UACR:
- Most sensitive for early detection: UACR detects microalbuminuria (≥30 mg/g), the earliest clinical manifestation of diabetic nephropathy
- Convenient and practical: Random spot collection requires no timed urine collection
- Corrects for urine concentration: Unlike albumin measurement alone, the creatinine correction accounts for variations in hydration status
- Guideline-recommended standard: Both ADA and KDIGO explicitly recommend this as the screening method of choice
Why Other Options Are Incorrect
Spot urine protein concentration and spot urine creatinine concentration alone are inadequate because they don't account for urine concentration variability and are susceptible to false-positive and false-negative results 1.
24-hour urine total protein is more burdensome, adds little to prediction or accuracy, and is not recommended for routine screening 1. It may be used for quantification in established disease but not for initial screening.
Dipstick urinalysis is less sensitive and specific. The guidelines note that "semiquantitative or qualitative (dipstick) screening will need to be confirmed by UACR values in an accredited laboratory" 1. It's better to simply start with UACR rather than use a less accurate test that requires confirmation.
Clinical Context for This Patient
This 45-year-old woman with type 2 diabetes requires annual CKD screening, which should include both UACR and eGFR 2. Her eGFR is already available (≥60 mL/min/1.73 m²), so the missing component is the UACR to complete the screening assessment. Given that CKD may already be present at type 2 diabetes diagnosis in up to 20-40% of patients 1, and she has additional risk factors (obesity with BMI 32, suboptimal glucose control with fasting glucose 183 mg/dL), screening with UACR is particularly important.
A UACR ≥30 mg/g indicates albuminuria and diagnoses CKD when persistent, triggering the need for evidence-based interventions including SGLT2 inhibitors, ACE inhibitors/ARBs, and potentially nonsteroidal mineralocorticoid receptor antagonists 2.